Last reviewed · How we verify
High-dose meropenem
High-dose meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
High-dose meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections caused by susceptible organisms, Bacterial meningitis, Hospital-acquired infections with resistant gram-negative bacteria.
At a glance
| Generic name | High-dose meropenem |
|---|---|
| Sponsor | National University of Singapore |
| Drug class | Carbapenem antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and leading to cell wall disruption and bacterial death. High-dose formulations are used to achieve elevated concentrations in tissues and cerebrospinal fluid, particularly for serious infections caused by resistant gram-negative organisms or in meningitis.
Approved indications
- Serious bacterial infections caused by susceptible organisms
- Bacterial meningitis
- Hospital-acquired infections with resistant gram-negative bacteria
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Seizures (particularly with meningitis or renal impairment)
- Phlebitis at injection site
Key clinical trials
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections. (NA)
- Pharmacokinetics of Meropenem During High-dose CRRT
- Pharmacokinetics of High-dose Tigecycline in Critically Ill Patients
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-dose meropenem CI brief — competitive landscape report
- High-dose meropenem updates RSS · CI watch RSS
- National University of Singapore portfolio CI